-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Genetron Health and Impair Pharmaceuticals announced that the two parties have reached a project cooperation in the process of drug research and subsequent development, in order to jointly promote the research of synthetic lethal inhibitors based on new targets and the development of companion diagnostic products
.
Regarding this cooperation, both parties expressed the hope that with each other's strength and advantages in related fields, they would work together to accelerate the research and development of new drugs and contribute to the global anti-cancer cause
.
It is understood that synthetic lethality is another important direction of anti-tumor drug discovery since molecular targeted therapy, and it has huge market potential
.
Taking the first marketed target PARP inhibitor for synthetic lethal therapy as an example, according to evaluate Pharma’s forecast, only four types (Olaparib, Niraparib, Niraparib, and Rucaparib) approved globally by 2020 will be considered.
(Rucaparib, Talazoparib), in the just past 2020, parib drugs already have a market share of nearly 2 to 3 billion U.
S.
dollars
.
By 2023, the global PARP inhibitor market is expected to exceed US$4.
5 billion
.
Facing the huge market prospects, pharmaceutical companies will certainly take action
.
It is reported that since the success of PARP inhibitors, a large amount of domestic and foreign resources have been invested in the research of synthetic lethal theory in order to obtain better tumor treatment drugs
.
Among them, Olaparib is one of the drugs that many pharmaceutical companies are paying close attention to
.
Currently, clinical trials in more cancer fields are also underway
.
According to data, Olaparib is an oral small molecule drug, which is a kind of PARP enzyme inhibitor.
It can inhibit the enzymes including PARP1, PARP2 and PARP3.
It is hailed by the industry as a star drug for synthetic lethality and is currently a very successful realization of the synthetic lethal principle.
Tumor-targeted drugs
.
It is worth mentioning that Olaparib was first approved by the FDA in 2014 for use in patients with advanced ovarian cancer related to BRCA gene mutations.
Since then, the indications have continued to expand.
.
According to Insight Global Clinical Database, as of May 2020, Olaparib has 248 ongoing clinical trials worldwide, involving different types of cancer, including gastric cancer, triple negative breast cancer, non-small cell lung cancer, small cell lung cancer, and colorectal cancer.
cancer, renal cancer, cervical cancer, melanoma
.
In China, Olaparib was approved by the National Food and Drug Administration in 2018 for the maintenance treatment of platinum-sensitive recurrent ovarian cancer.
The brand name is "Lipuzhuo" and became the first PARP inhibitor to enter China
.
According to data, the PARP inhibitor Liptrozol, which was jointly developed by AstraZeneca and Merck and used to treat ovarian cancer and breast cancer, exceeded the $1 billion mark in sales in 2019, with revenue of $1.
198 billion, a year-on-year increase of 89 %
.
In China, after the drug was included in the medical insurance catalogue in November 2019, it pushed emerging market sales to 133 million U.
S.
dollars, a year-on-year increase of 177%
.
In fact, in addition to Olaparib, many other related targets have entered the clinic, and they are progressing rapidly
.
Many varieties have entered into clinical phase III, II period, mostly for the global development companies large pharmaceutical companies such as AstraZeneca, Merck, Pfizer and so on
.
Of course, domestic pharmaceutical companies are also rushing to enter these fields and deploy generic drugs and innovative drugs for research and development
.
The industry expects that according to the current research and development trend, in the future, domestic and foreign pharmaceutical companies will make more breakthroughs in the research of synthetic lethal inhibitors, and as the results continue to appear, more patients will also be benefited
.
.
Regarding this cooperation, both parties expressed the hope that with each other's strength and advantages in related fields, they would work together to accelerate the research and development of new drugs and contribute to the global anti-cancer cause
.
It is understood that synthetic lethality is another important direction of anti-tumor drug discovery since molecular targeted therapy, and it has huge market potential
.
Taking the first marketed target PARP inhibitor for synthetic lethal therapy as an example, according to evaluate Pharma’s forecast, only four types (Olaparib, Niraparib, Niraparib, and Rucaparib) approved globally by 2020 will be considered.
(Rucaparib, Talazoparib), in the just past 2020, parib drugs already have a market share of nearly 2 to 3 billion U.
S.
dollars
.
By 2023, the global PARP inhibitor market is expected to exceed US$4.
5 billion
.
Facing the huge market prospects, pharmaceutical companies will certainly take action
.
It is reported that since the success of PARP inhibitors, a large amount of domestic and foreign resources have been invested in the research of synthetic lethal theory in order to obtain better tumor treatment drugs
.
Among them, Olaparib is one of the drugs that many pharmaceutical companies are paying close attention to
.
Currently, clinical trials in more cancer fields are also underway
.
According to data, Olaparib is an oral small molecule drug, which is a kind of PARP enzyme inhibitor.
It can inhibit the enzymes including PARP1, PARP2 and PARP3.
It is hailed by the industry as a star drug for synthetic lethality and is currently a very successful realization of the synthetic lethal principle.
Tumor-targeted drugs
.
It is worth mentioning that Olaparib was first approved by the FDA in 2014 for use in patients with advanced ovarian cancer related to BRCA gene mutations.
Since then, the indications have continued to expand.
.
According to Insight Global Clinical Database, as of May 2020, Olaparib has 248 ongoing clinical trials worldwide, involving different types of cancer, including gastric cancer, triple negative breast cancer, non-small cell lung cancer, small cell lung cancer, and colorectal cancer.
cancer, renal cancer, cervical cancer, melanoma
.
In China, Olaparib was approved by the National Food and Drug Administration in 2018 for the maintenance treatment of platinum-sensitive recurrent ovarian cancer.
The brand name is "Lipuzhuo" and became the first PARP inhibitor to enter China
.
According to data, the PARP inhibitor Liptrozol, which was jointly developed by AstraZeneca and Merck and used to treat ovarian cancer and breast cancer, exceeded the $1 billion mark in sales in 2019, with revenue of $1.
198 billion, a year-on-year increase of 89 %
.
In China, after the drug was included in the medical insurance catalogue in November 2019, it pushed emerging market sales to 133 million U.
S.
dollars, a year-on-year increase of 177%
.
In fact, in addition to Olaparib, many other related targets have entered the clinic, and they are progressing rapidly
.
Many varieties have entered into clinical phase III, II period, mostly for the global development companies large pharmaceutical companies such as AstraZeneca, Merck, Pfizer and so on
.
Of course, domestic pharmaceutical companies are also rushing to enter these fields and deploy generic drugs and innovative drugs for research and development
.
The industry expects that according to the current research and development trend, in the future, domestic and foreign pharmaceutical companies will make more breakthroughs in the research of synthetic lethal inhibitors, and as the results continue to appear, more patients will also be benefited
.